WO2015105981A3 - Nutritional composition comprising hmb for increasing or maintaining lean body mass in subjects having reduced leucine to hmb conversion efficiency or undergoing diabetic treatment - Google Patents

Nutritional composition comprising hmb for increasing or maintaining lean body mass in subjects having reduced leucine to hmb conversion efficiency or undergoing diabetic treatment Download PDF

Info

Publication number
WO2015105981A3
WO2015105981A3 PCT/US2015/010631 US2015010631W WO2015105981A3 WO 2015105981 A3 WO2015105981 A3 WO 2015105981A3 US 2015010631 W US2015010631 W US 2015010631W WO 2015105981 A3 WO2015105981 A3 WO 2015105981A3
Authority
WO
WIPO (PCT)
Prior art keywords
hmb
subjects
body mass
lean body
increasing
Prior art date
Application number
PCT/US2015/010631
Other languages
French (fr)
Other versions
WO2015105981A2 (en
Inventor
Neile Edens
Richard Gelling
Shreeram Sathyavageeswaran
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of WO2015105981A2 publication Critical patent/WO2015105981A2/en
Publication of WO2015105981A3 publication Critical patent/WO2015105981A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A method of increasing or maintaining lean body mass in leucine conversion-compromised subjects and subjects undergoing treatment for diabetes is provided. The method includes administering an effective amount of β-hydroxy-β-methylbutyrate (HMB) to a subject with compromised leucine conversion efficiency or a subject undergoing treatment for insulin resistance associated with diabetes. Administration of HMB to a leucine conversion-compromised subject or a subject undergoing treatment for diabetes is effective to increase or maintain the human's lean body mass.
PCT/US2015/010631 2014-01-09 2015-01-08 Conditional essentiality of hmb WO2015105981A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461925407P 2014-01-09 2014-01-09
US61/925,407 2014-01-09

Publications (2)

Publication Number Publication Date
WO2015105981A2 WO2015105981A2 (en) 2015-07-16
WO2015105981A3 true WO2015105981A3 (en) 2015-10-22

Family

ID=52463133

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/010631 WO2015105981A2 (en) 2014-01-09 2015-01-08 Conditional essentiality of hmb

Country Status (1)

Country Link
WO (1) WO2015105981A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3302704T (en) * 2015-06-01 2023-02-13 Metabolic Tech Llc Compositions and methods of use of beta-hydroxy-beta-methylbutyrate (hmb) for decreasing fat mass
CN105124586A (en) * 2015-09-18 2015-12-09 青岛琅琊台集团股份有限公司 Grape seed oil-containing DHA algae oil soft capsule compound and preparation method thereof
CN106075130A (en) * 2016-07-15 2016-11-09 甘肃青黛百年健康管理股份有限公司 A kind of Health-protection traditional Chinese medicinal preparation for fat-eliminating slimming
WO2018075867A1 (en) 2016-10-21 2018-04-26 Metabolic Technologies, Inc. COMPOSITIONS AND METHODS OF USE OF β-HYDROXY-β-METHYLBUTYRATE (HMB) AND PROBIOTICS
AU2019247478A1 (en) * 2018-04-06 2020-10-22 Abbott Laboratories Powdered nutritional compositions with HMB and protein system
CN108835628B (en) * 2018-07-24 2022-01-25 江苏菌钥生命科技发展有限公司 Weight-losing meal replacement powder and preparation method thereof
CN110800904A (en) * 2018-08-06 2020-02-18 丰宁平安高科实业有限公司 Solid beverage composition capable of effectively controlling weight and reducing fat and preparation method thereof
CN112715961A (en) * 2020-12-29 2021-04-30 北京康比特体育科技股份有限公司 Food composition for promoting muscle growth of elderly diabetic patients
WO2022225770A1 (en) * 2021-04-19 2022-10-27 Abbott Laboratories High protein liquid nutritional compositions
WO2022225786A1 (en) * 2021-04-22 2022-10-27 Abbott Laboratories Methods and compositions for improving muscle strength and/or reducing muscle loss
CN113841889A (en) * 2021-08-10 2021-12-28 许昌学院 Cell absorption combined functional nutrient
WO2023183767A1 (en) * 2022-03-21 2023-09-28 Abbott Laboratories Methods and compositions for increasing insulin sensitivity

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050215640A1 (en) * 2004-03-26 2005-09-29 Baxter Jeffrey H HMB compositions and uses thereof
WO2011075741A1 (en) * 2009-12-18 2011-06-23 Metabolic Technologies, Inc. Improved method of administering beta-hydroxy-beta-methylbutyrate (hmb)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1039892B1 (en) 1997-02-21 2004-04-28 Abbott Laboratories Use of polyunsaturated fatty acids for reducing the incidence of necrotizing enterocolitis
US6365218B1 (en) 2000-02-04 2002-04-02 Abbott Laboratories Pediatric formula and methods for providing nutrition and improving tolerance
US6811801B2 (en) 2001-12-12 2004-11-02 Abbott Laboratories Methods and compositions for brightening the color of thermally processed nutritionals

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050215640A1 (en) * 2004-03-26 2005-09-29 Baxter Jeffrey H HMB compositions and uses thereof
WO2011075741A1 (en) * 2009-12-18 2011-06-23 Metabolic Technologies, Inc. Improved method of administering beta-hydroxy-beta-methylbutyrate (hmb)

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HAO YANLEI ET AL: "beta-Hydroxy-beta-methylbutyrate reduces myonuclear apoptosis during recovery from hind limb suspension-induced muscle fiber atrophy in aged rats", AMERICAN JOURNAL OF PHYSIOLOGY: REGULATORY, INTEGRATIVE AND COMPARATIVE PHYSIOLOGY, AMERICAN PHYSIOLOGICAL SOCIETY, US, vol. 301, no. 3, 1 September 2011 (2011-09-01), pages R701 - R715, XP009156087, ISSN: 0363-6119, [retrieved on 20110601], DOI: 10.1152/AJPREGU.00840.2010 *
MICHAEL MENCONI ET AL: "Dexamethasone and corticosterone induce similar, but not identical, muscle wasting responses in cultured L6 and C2C12 myotubes", JOURNAL OF CELLULAR BIOCHEMISTRY, vol. 105, no. 2, 1 October 2008 (2008-10-01), pages 353 - 364, XP055177363, ISSN: 0730-2312, DOI: 10.1002/jcb.21833 *

Also Published As

Publication number Publication date
WO2015105981A2 (en) 2015-07-16

Similar Documents

Publication Publication Date Title
WO2015105981A3 (en) Nutritional composition comprising hmb for increasing or maintaining lean body mass in subjects having reduced leucine to hmb conversion efficiency or undergoing diabetic treatment
PH12017501217A1 (en) Methods of treating retinal diseases
MY167234A (en) Novel glucagon analogues
EA201590011A1 (en) PEPTIDE ANALOGUES EXENDIN-4
Thareja et al. En coup de sabre morphea treated with hyaluronic acid filler. Report of a case and review of the literature.
WO2015128403A3 (en) An a22k, desb27, b29r, des b30, at epsilon position of lysine 22 acylated human insulin analogue
FR2969495B1 (en) EXTRACT OF MACA-RICH AERIAL PARTS OF POLYPHENOLS AND COMPOSITION COMPRISING THE SAME
EA201691420A1 (en) COMPOSITIONS OF ENOLOGY 1 (ENO1) AND THEIR APPLICATION
MX2015014007A (en) TREATMENT OF DIABETES MELLITUS BY LONG–ACTING FORMULATIONS OF INSULINS.
TW201613592A (en) Glucose metabolism ameliorating agent
RU2018125622A (en) METHOD OF APPLICATION OF CARRYMICIN AGAINST RESISTANCE OF INFECTION PROVIDED BY MYCOBACTERIA TUBERCULOSIS
MX2018002223A (en) Novel insulin derivatives and the medical uses hereof.
SG10201906172XA (en) Regulation of glucose metabolism using anti-cgrp antibodies
PH12017501290A1 (en) Treatment of pediatric type 2 diabetes mellitus patients with lixisenatide
PH12017500392A1 (en) Medical treatments based on anamorelin
PH12017501304A1 (en) Levodopa and carbidopa intestinal gel and method of use
MX2022014577A (en) Levodopa and carbidopa intestinal gel and methods of use.
MX2017000878A (en) Marine peptides and fish nucleotides, compositions and uses thereof for reducing blood glucose.
Chaabane Paracetamol/codeine
MX364643B (en) Treatment of type 2 diabetes with fty720.
Gulec Pityriasis rosea-like adverse reaction: case report
WO2020018058A3 (en) The injectable micronized human insulin
Ozturk New onset diabetes mellitus post transplantation and diabetic ketoacidosis: case report
Celik Hyperchloraemia in an infant: case report
Nakagami et al. Erratum to: Evaluation of add-on therapy of sitagliptin in Japanese patients with type 2 diabetes under insulin therapy

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15703335

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15703335

Country of ref document: EP

Kind code of ref document: A2